4th CEE 2018 – Presentations


Thursday 11 October

 Session 1 - Epidemiology of HIV and hepatitis in the CEE countries

Epidemiology of HIV Infection and Treatment in Europe
Teymur Noori, MSc - European Centre for Disease Prevention and Control (ECDC), Solna, Sweden

 Update on changes in Hepatitis B and C in CEE countries
Miłosz Parczewski, MD, PhD - Pomeranian Medical University, Szczecin, Poland



Country models: what has and what hasn’t worked
Nikoloz Chkhartishvili, MD, MS, PhD - Infectious Diseases,
AIDS And Clinical Immunology Research Center, Tbilisi, Georgia


Zahedul Islam, MBA - Alliance for Public Health, Kiev, Ukraine

 Session 2 - Challenges in HIV and viral hepatitis
 Hepatitis Delta: what are the new developments, what are the challenges?
Cihan Yurdaydin, MD, PhD - Ankara University Medical Centre, Ankara, Turkey
 HIV & women’s health: do we have any game changers here?
Mariana Mardarescu, MD, PhD - Institute for Infectious Disease M. Bals, Bucharest, Romania
 Special Session
 Aster, Viktor 2015_120Treatment-experienced patients in Central and Eastern Europe – What needs to be done?
Viktor Aster, Czech Republic
 Session 3 - Switching HIV therapy: considerations and strategies
 Clinical considerations in switching antiretroviral therapy
David Jilich, MD - HIV Centre Prague, Prague, Czech Republic
 Clinical Case Discussion: Switching HIV Therapy
Pavel Khaykin, MD (Presentation performed by Jurgen Rockstroh)
MainFachArtzt, Frankfurt Am Main, Germany
 Session 4 - Abstract-driven Presentations
 Real-life effectiveness of ledipasvir/sofosbuvir regimen and factors associated with retention in care among HIV/HCV co-infected PWID in Ukraine
Tetyana Kyrychenko, Ukraine
 Possible misclassification of HIV transmission between men: results of phylogenetic analysis
Natia Dvali, Georgia
 Epidemiology of HIV in the Baltic countries (Estonia, Latvia, Lithuania)
Saulius Caplinskas, Lithuania
 Spontaneous HCV clearance in HCV/HIV coinfected patients from AIDS Center Prague
Viktor Aster, Czech Republic

Friday 12 October

 Session 5 - Management of hepatitis C

Critical assessment of the global epidemiology of HCV
Peter Ferenci, MD - University of Vienna, Vienna, Austria

 Liver transplantation for HCV and HBV in The Czech Republic
Soña Frankova, MD, PhD - IKEM Prague transplant center, Prague,
Czech Republic
 Case Study: The changing IV drug use problem/pattern and what that means to the epidemic
Mojca Maticic, MD, PhD - University Medical Centre Ljubljana,
Ljubljana, Slovenia

The EpiTer-2 database
Robert Flisiak, MD, PhD - Medical University of Bialystok, Bialystok, Poland

 Session 6 - Hepatitis B cure strategies: how far are we?

Wedemeyer, Heiner 2014_120-160Hepatitis B cure strategies: how far are we? 
Heiner Wedemeyer, MD - University Clinic Essen, Essen, Germany

 Abstract-driven Presentations
 Mortality and causes of death among HIV/HCV co-infected persons in the Eastern European country of Georgia
Akaki Abutidze, Georgia
 HCV resistance-associated variants among HCV treatment naïve HIV-coinfected patients in Ukraine. A pilot study
Marta Vasylyev, Ukraine
 Session 7 - Hot topics in HIV and hepatitis
 New delivery systems and long acting antiretroviral drugs
David Back, PhD - University of Liverpool, Liverpool, United Kingdom
Pep Coll, MD - Hospital Universitari Germans Trias i Pujol, Badalona, Spain
 Abstract-driven Presentations
 Early results of pre-exposure prophylaxis program in Georgia
Nikoloz Chkhartishvili, Georgia
 The Regression of Liver Fibrosis in HCV Cirrhotic Patients Who Registered SVR after DAA Therapy
Anca Leustean, Romania
 Insulin-like growth factor and platelet-derived growth factor in liver cells of patients with chronic hepatitis C at different stages of fibrosis
Igor Tikhonov, Russia